| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,053,690 | 30 | 100 |
| Gagnon Robert E. | director | 0 | $0 | 1 | $2,587 | $-2,587 |
| Stuglik Brian M | director | 0 | $0 | 1 | $5,411 | $-5,411 |
| Bunn Paul A. | director | 0 | $0 | 1 | $62,500 | $-62,500 |
| Calkins Daniel | Chief Financial Officer | 0 | $0 | 5 | $74,749 | $-74,749 |
| Kauffman Michael | director | 0 | $0 | 1 | $85,500 | $-85,500 |
| Paterson Dan | President and CEO | 0 | $0 | 22 | $855,090 | $-855,090 |
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the …
Over the last 12 months, insiders at Verastem, Inc. have bought $0 and sold $1.05M worth of Verastem, Inc. stock.
On average, over the past 5 years, insiders at Verastem, Inc. have bought $0 and sold $515,570 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $108,500 was made by BARBERICH TIMOTHY J (director) on 2020‑12‑04.
| 2026-10-01 | Sale | Paterson Dan | President and CEO | 44,121 0.0508% | $8.00 | $352,968 | +16.58% | |
| 2026-10-01 | Sale | Calkins Daniel | Chief Financial Officer | 2,566 0.003% | $8.00 | $20,528 | +16.58% | |
| 2026-09-21 | Sale | Calkins Daniel | Chief Financial Officer | 55 <0.0001% | $7.70 | $424 | +4.76% | |
| 2026-08-03 | Sale | Paterson Dan | President and CEO | 1,302 0.0014% | $5.81 | $7,565 | +36.20% | |
| 2026-06-22 | Sale | Paterson Dan | President and CEO | 20,871 0.0296% | $4.18 | $87,241 | +72.24% | |
| 2026-06-22 | Sale | Calkins Daniel | Chief Financial Officer | 4,089 0.0058% | $4.18 | $17,089 | +72.24% | |
| 2026-05-04 | Sale | Paterson Dan | President and CEO | 806 0.0011% | $5.82 | $4,691 | +3.87% | |
| 2026-02-04 | Sale | Paterson Dan | President and CEO | 970 0.0016% | $6.69 | $6,489 | -12.96% | |
| 2026-01-12 | Sale | Paterson Dan | President and CEO | 10,321 0.0172% | $7.16 | $73,898 | -15.33% | |
| 2026-01-12 | Sale | Calkins Daniel | Chief Financial Officer | 5,039 0.0084% | $7.16 | $36,079 | -15.33% | |
| 2025-12-24 | Sale | Calkins Daniel | Chief Financial Officer | 80 0.0001% | $7.86 | $629 | -22.49% | |
| 2025-12-16 | Sale | Paterson Dan | President and CEO | 393 0.0007% | $9.14 | $3,592 | -28.82% | |
| 2025-12-16 | Sale | Stuglik Brian M | director | 592 0.001% | $9.14 | $5,411 | -28.82% | |
| 2025-12-16 | Sale | Gagnon Robert E. | director | 283 0.0005% | $9.14 | $2,587 | -28.82% | |
| 2025-12-11 | Sale | Paterson Dan | President and CEO | 2,000 0.0035% | $10.00 | $20,000 | -34.41% | |
| 2025-12-10 | Sale | Paterson Dan | President and CEO | 2,000 0.0033% | $10.07 | $20,140 | -38.16% | |
| 2025-12-09 | Sale | Paterson Dan | President and CEO | 2,000 0.0033% | $10.25 | $20,500 | -38.64% | |
| 2025-12-08 | Sale | Paterson Dan | President and CEO | 2,000 0.0034% | $10.50 | $21,000 | -39.22% | |
| 2025-12-05 | Sale | Paterson Dan | President and CEO | 2,000 0.0034% | $10.61 | $21,220 | -39.86% | |
| 2025-12-04 | Sale | Paterson Dan | President and CEO | 2,000 0.0031% | $10.00 | $20,000 | -41.23% |
| Paterson Dan | President and CEO | 652712 0.7207% | $6.38M | 5 | 56 | <0.0001% |
| Stuglik Brian M | director | 101147 0.1117% | $988,206.19 | 1 | 30 | <0.0001% |
| Kauffman Michael | director | 8666 0.0096% | $84,666.82 | 2 | 3 | <0.0001% |
| CLARKE JOHN K | director | 2329121 2.5718% | $22.76M | 7 | 0 | +26.77% |
| CHP III LP | 10 percent owner | 2329121 2.5718% | $22.76M | 7 | 0 | +26.77% |
| MPM BIOVENTURES V LLC | 2033333 2.2452% | $19.87M | 1 | 0 | ||
| GADICKE ANSBERT | director | 2029593 2.2411% | $19.83M | 1 | 0 | |
| Westphal Christoph H | Executive Chairman | 1230769 1.359% | $12.02M | 12 | 0 | +22.02% |
| ALDRICH RICHARD | director | 408142 0.4507% | $3.99M | 21 | 0 | <0.0001% |
| Forrester Robert | President and CEO | 221234 0.2443% | $2.16M | 7 | 0 | <0.0001% |
| BARBERICH TIMOTHY J | director | 218000 0.2407% | $2.13M | 7 | 0 | <0.0001% |
| Bessemer Venture Partners VII L.P. | 100000 0.1104% | $977,000.00 | 1 | 0 | ||
| Pachter Jonathan | VP, Head of Research | 66955 0.0739% | $654,150.35 | 1 | 0 | +19.12% |
| TERMEER HENRI A | director | 32179 0.0355% | $314,388.83 | 3 | 0 | +26.99% |
| Phanstiel S. Louise | director | 26500 0.0293% | $258,905.00 | 4 | 0 | +28.84% |
| Lobacki Joseph M | Executive VP & CCO | 10700 0.0118% | $104,539.00 | 2 | 0 | <0.0001% |
| Bloom Steven H. | Chief Strategy Officer | 3500 0.0039% | $34,195.00 | 1 | 0 | <0.0001% |
| FRIEDMAN PAUL A | director | 3000 0.0033% | $29,310.00 | 1 | 0 | |
| SHERWIN STEPHEN A | director | 2500 0.0028% | $24,425.00 | 1 | 0 | |
| GREEN JOHN B | Chief Financial Officer | 2500 0.0028% | $24,425.00 | 4 | 0 | +19.12% |
| Lawton Alison Frances | director | 2500 0.0028% | $24,425.00 | 1 | 0 | |
| Rowinsky Eric K | director | 2000 0.0022% | $19,540.00 | 1 | 0 | +8.33% |
| Singh Monica | General Counsel | 2000 0.0022% | $19,540.00 | 2 | 0 | |
| Horobin Joanna | Chief Medical Officer | 750 0.0008% | $7,327.50 | 1 | 0 | |
| Kraus Stephen | director | 0 0% | $0 | 1 | 0 |
$100,473,344 | 83 | 9.53% | $826.91M | |
$15,410,062 | 81 | 39.69% | $975.93M | |
Verastem, Inc. (VSTM) | $5,911,307 | 70 | -1.38% | $884.8M |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$11,663,618 | 57 | 32.20% | $934.29M |
| Increased Positions | 97 | +83.62% | 32M | +53.84% |
| Decreased Positions | 50 | -43.1% | 15M | -25.48% |
| New Positions | 47 | New | 15M | New |
| Sold Out Positions | 20 | Sold Out | 5M | Sold Out |
| Total Postitions | 163 | +40.52% | 76M | +28.35% |
| Rtw Investments, Lp | $39,232.00 | 7.24% | 5.43M | +1M | +27.63% | 2025-09-30 |
| Balyasny Asset Management L.P. | $29,981.00 | 5.53% | 4.15M | -59,206 | -1.41% | 2025-09-30 |
| Logos Global Management Lp | $29,282.00 | 5.4% | 4.05M | +3M | +305% | 2025-09-30 |
| Point72 Asset Management, L.P. | $28,048.00 | 5.17% | 3.88M | +4M | New | 2025-09-30 |
| Blackrock, Inc. | $26,875.00 | 4.96% | 3.72M | +958,268 | +34.73% | 2025-09-30 |
| Vanguard Group Inc | $25,153.00 | 4.64% | 3.48M | +55,394 | +1.62% | 2025-09-30 |
| Stonepine Capital Management, Llc | $19,304.00 | 3.56% | 2.67M | +1M | +96.27% | 2025-09-30 |
| Vivo Capital, Llc | $19,123.00 | 3.53% | 2.64M | +1M | +71.92% | 2025-09-30 |
| Foresite Capital Management Vi Llc | $18,907.00 | 3.49% | 2.62M | +1M | +104.86% | 2025-09-30 |
| State Street Corp | $16,113.00 | 2.97% | 2.23M | -22,784 | -1.01% | 2025-09-30 |